MedTrace Logo

Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC

NCT06603402 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2024-12-03

No results posted yet for this study

Summary

The aim of this clinical trial is to evaluate whether low-dose involved-field radiotherapy combined with immunochemotherapy can reduce treatment-related adverse effects, enhance progression-free survival (PFS), and improve overall survival (OS) in patients with locally advanced, unresectable esophageal squamous cell carcinoma.

The key questions this study seeks to address are:

* Can low-dose involved-field radiotherapy combined with immunochemotherapy reduce treatment-related adverse effects?
* Does this combined approach improve PFS and OS in these patients?

Participants in the study will:

* Undergo an endoscopy at West China Hospital to confirm their diagnosis.
* Receive a treatment regimen that includes low-dose radiotherapy at 45.0 Gy in 1.8 Gy per fraction over 25 fractions, alongside immunochemotherapy, with three cycles of chemotherapy administered every 3 weeks.
* After completing the full treatment regimen, participants will undergo regular follow-up visits and monitoring by healthcare professionals.

Conditions

  • Esophageal Squamous Cell Carcinoma (ESCC)
  • Immunotherapy

Interventions

RADIATION

low-dose involved-field radiotherapy combined with immunochemotherapy

low-dose involved-field radiotherapy combined with immunochemotherapy

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Principal Investigators

  • zhenyu ding, MD · West China Hospital, Sichuan University, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-24
Primary Completion
2025-03-01
Completion
2025-09-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06603402 on ClinicalTrials.gov